NCT06482957 Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
| NCT ID | NCT06482957 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,100 participants |
| Start Date | 2022-04-01 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,100 participants in total. It began in 2022-04-01 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the impact that a sarcoma diagnosis and treatment have had on patients over time.
Eligibility Criteria
Patients at any age with a history of sarcoma, with or without evidence of a persistent disease • For pediatric patients * Parent/primary caregiver of patient * Sibling of patient aged 8 years or older
Contact & Investigator
Debra Friedman, MD
PRINCIPAL INVESTIGATOR
Vanderbilt University/Ingram Cancer Center
Frequently Asked Questions
Who can join the NCT06482957 clinical trial?
This trial is open to participants of all sexes, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06482957 currently recruiting?
Yes, NCT06482957 is actively recruiting participants. Contact the research team at cip@vumc.org for enrollment information.
Where is the NCT06482957 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06482957 clinical trial?
NCT06482957 is sponsored by Vanderbilt-Ingram Cancer Center. The principal investigator is Debra Friedman, MD at Vanderbilt University/Ingram Cancer Center. The trial plans to enroll 2,100 participants.